Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy

• Eric B. CohenAbbVie (United States)
• Arie RegevEli Lilly (United States)
• Anju GargSanofi (United States)
• Adrian M. Di BisceglieSaint Louis University
• James H. LewisGeorgetown University
• John Moore VierlingBaylor College of Medicine
• Judith Hey‐HadaviPfizer (United States)
• Klaudia M. SteplewskiGlaxoSmithKline (United States)
• Anna FettiplaceAstraZeneca (United Kingdom)
• Chunlin L. ChenBayer (Germany)
• Nonko PehlivanovMerck & Co., Inc., Rahway, NJ, USA (United States)
• Stuart F. W. KendrickGlaxoSmithKline (United Kingdom)
• Mark AviganUnited States Food and Drug Administration